Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis
Z Shubber, EJ Mills, JB Nachega, R Vreeman… - PLoS …, 2016 - journals.plos.org
Background Maintaining high levels of adherence to antiretroviral therapy (ART) is a
challenge across settings and populations. Understanding the relative importance of …
challenge across settings and populations. Understanding the relative importance of …
Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management
A review of 77 studies employing self-report measures of antiretroviral adherence published
1/1996 through 8/2004 revealed great variety in adherence assessment item content, format …
1/1996 through 8/2004 revealed great variety in adherence assessment item content, format …
Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders
Objective: There is limited evidence on whether growing mobile phone availability in sub-
Saharan Africa can be used to promote high adherence to antiretroviral therapy (ART). This …
Saharan Africa can be used to promote high adherence to antiretroviral therapy (ART). This …
Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International …
MA Thompson, MJ Mugavero, KR Amico… - Annals of internal …, 2012 - acpjournals.org
Description: After HIV diagnosis, timely entry into HIV medical care and retention in that care
are essential to the provision of effective antiretroviral therapy (ART). Adherence to ART is …
are essential to the provision of effective antiretroviral therapy (ART). Adherence to ART is …
Potential influences of the COVID-19 pandemic on drug use and HIV care among people living with HIV and substance use disorders: experience from a pilot mHealth …
KR Hochstatter, WZ Akhtar, S Dietz, K Pe-Romashko… - AIDS and Behavior, 2021 - Springer
People living with HIV (PLWH) and substance use disorder (SUD) are particularly
vulnerable to harmful health consequences of the global COVID-19 pandemic. The health …
vulnerable to harmful health consequences of the global COVID-19 pandemic. The health …
In Situ Forming, Enzyme-Responsive Peptoid-Peptide Hydrogels: An Advanced Long-Acting Injectable Drug Delivery System
SM Coulter, S Pentlavalli, Y An, LK Vora… - Journal of the …, 2024 - ACS Publications
Long-acting drug delivery systems are promising platforms to improve patient adherence to
medication by delivering drugs over sustained periods and removing the need for patients to …
medication by delivering drugs over sustained periods and removing the need for patients to …
Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa
JB Nachega, M Hislop, H Nguyen… - JAIDS Journal of …, 2009 - journals.lww.com
Objective: To determine adherence to and effectiveness of antiretroviral therapy (ART) in
adolescents vs. adults in southern Africa. Design: Observational cohort study. Setting: Aid for …
adolescents vs. adults in southern Africa. Design: Observational cohort study. Setting: Aid for …
Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm
To date, six clinical trials have explored the efficacy of pre-exposure prophylaxis (PrEP)
against HIV infection using oral tenofovir and/or emtricitabine/tenofovir [1–6]. Efficacy ranged …
against HIV infection using oral tenofovir and/or emtricitabine/tenofovir [1–6]. Efficacy ranged …
Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression
DR Bangsberg - Clinical infectious diseases, 2006 - academic.oup.com
For antiretroviral therapy, the 95% adherence “threshold” is based on nucloside-exposed
patients who are receiving partially suppressive, unboosted protease inhibitor regimens …
patients who are receiving partially suppressive, unboosted protease inhibitor regimens …
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
Background Long-acting injectable cabotegravir is a novel integrase inhibitor currently in
advanced clinical development for HIV prevention and treatment. We aimed to assess the …
advanced clinical development for HIV prevention and treatment. We aimed to assess the …